公开(公告)号：EP2326633A1

公开(公告)日：2011-06-01

申请号：EP09792299.1

申请日：2009-09-08

Applicant: Bristol-Myers Squibb Company

Inventor： YEUNG, Kap-Sun ,  PARCELLA, Kyle E. ,  BENDER, John A. ,  BENO, Brett R. ,  GRANT-YOUNG, Katharine A. ,  HAN, Ying ,  HEWAWASAM, Piyasena ,  KADOW, John F. ,  NICKEL, Andrew

IPC: C07D307/84 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12 ,  C07D417/10 ,  C07D417/12 ,  C07D453/00 ,  C07D491/10 ,  A61K31/14 ,  A61P31/14

CPC classification number: C07D307/84 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12 ,  C07D417/10 ,  C07D417/12 ,  C07D453/00 ,  C07D491/10

Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Abstract translation: 本公开提供了式I的化合物，包括它们的盐，以及使用这些化合物的组合物和方法。 该化合物对丙型肝炎病毒（HCV）具有活性，并可用于治疗感染HCV的患者。

公开(公告)号：EP2024375B1

公开(公告)日：2011-03-09

申请号：EP07761873.4

申请日：2007-05-04

Applicant: Bristol-Myers Squibb Company

Inventor： BENDER, John A. ,  DING, Min ,  GENTLES, Robert G. ,  HEWAWASAM, Piyasena

IPC: C07D519/00 ,  A61P31/12 ,  A61K31/55

CPC classification number: C07D519/00

Abstract: The invention encompasses compounds of formula (I) as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Abstract translation: 本发明包括式（I）的化合物以及使用该化合物的组合物和方法。 这些化合物对丙型肝炎病毒（HCV）具有活性，可用于治疗HCV感染者。

公开(公告)号：EP2209789A1

公开(公告)日：2010-07-28

申请号：EP07874300.2

申请日：2007-11-20

Applicant: Bristol-Myers Squibb Company

Inventor： BENDER, John A. ,  DING, Min ,  GENTLES, Robert G. ,  HEWAWASAM, Piyasena

IPC: C07D487/08 ,  A61K31/55 ,  A61P31/12

CPC classification number: C07D487/08

Abstract: The invention encompasses compounds of formula (I) as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

公开(公告)号：EP2118110A1

公开(公告)日：2009-11-18

申请号：EP08743824.8

申请日：2008-03-13

Applicant: Bristol-Myers Squibb Company

Inventor： YEUNG, Kap-sun ,  BENDER, John A. ,  GENTLES, Robert G. ,  YANG, Zhong ,  DING, Min ,  TU, Yong ,  HEWAWASAM, Piyasena ,  HAN, Ying ,  KADOW, John F.

IPC: C07D487/04 ,  A61K31/55 ,  A61P31/12 ,  C07D519/00

CPC classification number: C07D487/04 ,  C07D519/00

Abstract: The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

公开(公告)号：EP2024375A1

公开(公告)日：2009-02-18

申请号：EP07761873.4

申请日：2007-05-04

Applicant: Bristol-Myers Squibb Company

Inventor： BENDER, John A. ,  DING, Min ,  GENTLES, Robert G. ,  HEWAWASAM, Piyasena

IPC: C07D519/00 ,  A61P31/12 ,  A61K31/55

CPC classification number: C07D519/00

Abstract: The invention encompasses compounds of formula (I) as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

公开(公告)号：EP1904516A2

公开(公告)日：2008-04-02

申请号：EP06786607.9

申请日：2006-07-10

Applicant: Bristol-Myers Squibb Company

Inventor： HEWAWASAM, Piyasena ,  DING, Min ,  SUN, Li-Qiang ,  SCOLA, Paul Michael

IPC: C07K5/08 ,  A61K38/06 ,  C07D207/14 ,  C07D207/16

CPC classification number: C07K5/0808 ,  A61K38/00

Abstract: The present disclosure relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Abstract translation: 本公开涉及用于治疗丙型肝炎病毒（HCV）感染的三肽化合物，组合物和方法。 还公开了含有这些化合物的药物组合物以及使用这些化合物治疗HCV感染的方法。

公开(公告)号：EP1133474B1

公开(公告)日：2007-02-21

申请号：EP99960636.1

申请日：1999-12-01

Applicant: Bristol-Myers Squibb Company

Inventor： HEWAWASAM, Piyasena ,  STARRETT, John, E., Jr.

IPC: C07D215/227

CPC classification number: C07D215/227 ,  C07D215/54

Abstract: The present invention provides novel 3-substituted-4-arylquinolin-2-one derivatives having general formula (I) wherein R, R?1, R2, R3, R4, R5, R6 and R7¿ are as defined herein, or a nontoxic pharmaceutically acceptable salt thereof which are modulators of the large conductance calcium-activated K+ channels and are useful in the treatment of disorders which are responsive to the opening of the potassium channels.

Abstract translation: 本发明提供了具有通式R，R 1，R 2，R 3，R 4，R 5，R 6和R 7如本文所定义的新的3-取代-4-芳基喹啉-2-酮衍生物或其无毒的药学上可接受的盐 其是大电导钙激活的K +通道的调节剂，并且可用于治疗对钾通道开放有反应的病症。

公开(公告)号：EP0946173B1

公开(公告)日：2005-05-18

申请号：EP97909835.7

申请日：1997-10-07

Applicant: Bristol-Myers Squibb Company

Inventor： PENDRI, Yadagiri, R. ,  MARTINEZ, Eduardo, J. ,  THOTTATHIL, John, K. ,  HEWAWASAM, Piyasena

IPC: A61K31/405 ,  C07D209/34 ,  C07C205/56 ,  C07C201/16

CPC classification number: C07C201/16 ,  C07C201/12 ,  C07C205/56 ,  C07C227/04 ,  C07C229/42 ,  C07D209/34 ,  Y02P20/55

Abstract: The present invention relates to novel itermediates of formula (1) wherein the wavy bond (∩ ∩) represents the racemate, the (R)-enantiomer or the (S)-enantiomer; and R is hydrogen, a carboxyl-protecting group or a cation of an addition salt; or solvate thereof; and to the use thereof in a process for the preparation of certain 3-fluoro oxindole derivatives.

Abstract translation: （R） - 对映体或（S） - 对映体;本发明涉及式（1） 并且R是氢，羧基保护基或加成盐的阳离子; 或其溶剂化物; 并涉及其在制备某些3-氟羟吲哚衍生物的方法中的用途。

公开(公告)号：EP1363624A2

公开(公告)日：2003-11-26

申请号：EP02714888.1

申请日：2002-02-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： HEWAWASAM, Piyasena ,  DEXTRAZE, Pierre ,  GRIBKOFF, Valentin, K. ,  KINNEY, Gene, G. ,  DWORETZKY, Steven, I.

IPC: A61K31/404

CPC classification number: C07D209/34

Abstract: There is provided novel 3-fluoro-3-phenyl oxindole derivatives of Formula I wherein R?1, R2, R3 and R4¿ each are independently hydrogen, C¿1-4? alkyl, halogen, fluoromethyl, trifluoromethyl, phenyl, 4-methylphenyl or 4-trifluoromethylphenyl; R?5¿ is C¿1-6? alkyl optionally substituted with one to three same or different groups selected from fluoro and chloro, provided R?5¿ is not C¿1-6? alkyl when Y is O; Y is O or S; and R?6 and R7¿ each are independently hydrogen, chloro, bromo or trifluoromethy; which are openers of the KCNQ potassium channels and are useful in the treatment of disorders which are responsive to the opening of the KCNQ potassium channels.

公开(公告)号：EP1361879A1

公开(公告)日：2003-11-19

申请号：EP02709517.3

申请日：2002-02-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： HEWAWASAM, Piyasena ,  DODD, Dharmpal, S. ,  WEAVER, Charles, D. ,  DEXTRAZE, Pierre ,  GRIBKOFF, Valentin, K. ,  KINNEY, Gene, G. ,  DWORETZKY, Steven, I.

IPC: A61K31/505 ,  A61P25/06

CPC classification number: C07D239/42 ,  C07D405/12 ,  C07D409/04 ,  C07D409/12

Abstract: There is provided a method of treatment for disorders responsive to the modulation of KCNQ potassium channels by administering to a mammal in need thereof a therapeutically effective amount of a 2,4-disubstituted pyrimidine-5-carboxamide derivative of Formula (I) wherein R?1, R2, R3, R4 and R5¿ are as defined in the description. The present invention also provides pharmaceutical compositions comprising openers or activators of the KCNQ potassium channels and especially to the method of treatment of disorders sensitive to KCNQ potassium channel opening activity such as migraine.